Pharma R&D is at a crossroads: the pressure to accelerate innovation, ensure compliance and manage fragmented data has never ...

While rare disease research has advanced significantly, related expertise and data are scattered across too many disconnected places.

In a rare move, nonprofit organization Blood Cancer United is buying the remaining supplies of a discontinued investigational ...

A new AI model has become so good at predicting how molecules evolve over time that, in the future, it could speed up the ...

This Brush Up is sponsored by MilliporeSigma. Learn more about therapeutic synthesis pathways. Drug development is a process that spans many years, from the initial phase of identifying potential drug ...

Monash University's Andrew R. Snyder, PhD. joins the show to discuss Daraxonrasib, a novel RAS(ON) inhibitor, doubled median ...

Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

Drug discovery has traditionally been slow and expensive, often taking decades and costing manufacturers billions. Traditional methods, while advancing, are hitting limits in tackling the complexities ...

If you ask the commissioner of the US Food and Drug Administration about the greatest hurdles to treating disease in the US, he doesn’t point to any of the scientific problems his agency is working on ...